Pharmacokinetics and safety profile of oxaliplatin
- PMID: 9609104
Pharmacokinetics and safety profile of oxaliplatin
Abstract
In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal cancer, both as a single agent and in combination with 5-fluorouracil (5-FU) and folinic acid (FA). Oxaliplatin differs from cisplatin in its lack of nephrotoxicity and from carboplatin in its hematologic toxicity being mild. The most constant acute side effect of oxaliplatin observed in clinical trials was a transient peripheral neuropathy manifesting as paresthesia and dysesthesia in the extremities, triggered or enhanced by exposure to cold. The neurosensory phenomena, dependent on the cumulative dose of oxaliplatin, affect all patients who receive doses > or = 540 mg/m2 over four cycles or more of therapy. This neurologic toxicity is also highly reversible, with 82% of patients having their neuropathy regress within 4 to 6 months and 41% experiencing complete recovery within 6 to 8 months. With these considerations in mind, the currently recommended dosing schedules for oxaliplatin are 130 mg/m2/d as a 2- to 6-hour infusion or 175 mg/m2/d as a chronomodulated infusion over 5 days, both of which are administered every 3 weeks. Oxaliplatin rapidly disappears from the plasma and is rapidly transformed into putative active species. 5-Fluorouracil and folinic acid, often used in combination with oxaliplatin, do not affect its pharmacokinetics. The favorable pharmacokinetics and safety profile of oxaliplatin contribute to its tolerability, particularly in pretreated cancer patients with reduced renal function. The reversible nature of its dose-limiting neurotoxicity and its synergistic action with 5-FU/FA make oxaliplatin an interesting agent for the treatment of colorectal cancer and for other potential indications.
Similar articles
-
Oxaliplatin-related neurotoxicity: how and why?Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. doi: 10.1016/j.critrevonc.2006.01.001. Epub 2006 Jun 27. Crit Rev Oncol Hematol. 2006. PMID: 16806962 Review.
-
Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.Anticancer Res. 2003 Nov-Dec;23(6D):5203-8. Anticancer Res. 2003. PMID: 14981990 Clinical Trial.
-
Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.J Clin Oncol. 2007 Jun 1;25(16):2274-80. doi: 10.1200/JCO.2006.08.2388. J Clin Oncol. 2007. PMID: 17538173 Clinical Trial.
-
Clinical pharmacokinetics of oxaliplatin: a critical review.Clin Cancer Res. 2000 Apr;6(4):1205-18. Clin Cancer Res. 2000. PMID: 10778943 Review.
-
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.Clin Cancer Res. 1997 Jun;3(6):891-9. Clin Cancer Res. 1997. PMID: 9815764 Clinical Trial.
Cited by
-
Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.Mol Pain. 2009 Nov 18;5:66. doi: 10.1186/1744-8069-5-66. Mol Pain. 2009. PMID: 19922644 Free PMC article.
-
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.Med Oncol. 2013 Mar;30(1):358. doi: 10.1007/s12032-012-0358-x. Epub 2012 Dec 25. Med Oncol. 2013. PMID: 23266940 Clinical Trial.
-
Neurotoxicity caused by the treatment with platinum analogues.Chemother Res Pract. 2011;2011:843019. doi: 10.1155/2011/843019. Epub 2011 Jun 27. Chemother Res Pract. 2011. PMID: 22312559 Free PMC article.
-
Injury-induced cold sensitization in Drosophila larvae involves behavioral shifts that require the TRP channel Brv1.PLoS One. 2018 Dec 26;13(12):e0209577. doi: 10.1371/journal.pone.0209577. eCollection 2018. PLoS One. 2018. PMID: 30586392 Free PMC article.
-
Anaesthesia in a Toxic Environment: Pressurised Intraperitoneal Aerosol Chemotherapy: A Retrospective Analysis.Turk J Anaesthesiol Reanim. 2020 Aug;48(4):273-279. doi: 10.5152/TJAR.2019.15493. Epub 2019 Dec 26. Turk J Anaesthesiol Reanim. 2020. PMID: 32864641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources